Citi raised the firm’s price target on MacroGenics to $25 from $13 and keeps a Buy rating on the shares following the Q4 report. The attributes the recent stock rally to the company’s increasing focus on developing antibody-drug conjugate and promising prior data along with upcoming catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGNX:
- MacroGenics price target raised to $24 from $18 at BMO Capital
- MacroGenics price target raised to $29 from $17 at Stifel
- MacroGenics price target raised to $25 from $23 at Barclays
- MacroGenics reports FY23 EPS (15c) , consensus 37c
- MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
